---
title: "STOK: Phase III trial for zorevunersen exceeds enrollment, shows zero dropouts, and targets 2027 NDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295690734.md"
description: "EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T16:26:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295690734.md)
  - [en](https://longbridge.com/en/news/295690734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295690734.md)
generator: "portal-rs"
---

# STOK: Phase III trial for zorevunersen exceeds enrollment, shows zero dropouts, and targets 2027 NDA

EMPEROR phase III trial for zorevunersen in Dravet syndrome shows strong patient retention, zero dropouts, and promising long-term functional gains. Rolling NDA submission is planned for 2027, with payers and prescribers valuing the drug's disease-modifying potential and long-term data.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [STOK.US](https://longbridge.com/en/quote/STOK.US.md)

## Related News & Research

- [STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones](https://longbridge.com/en/news/298493516.md)
- [Stoke Therapeutics CEO, chief patient officer to present at Cantor Global Healthcare Conference](https://longbridge.com/en/news/297781976.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)
- [RCUS: Casdatifan and quemliclustat lead a robust pipeline with strong late-stage data and major market potential](https://longbridge.com/en/news/298364956.md)
- [ORIC: Late-stage oncology programs advance with key data and expansion plans, backed by strong funding](https://longbridge.com/en/news/298496005.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**